Aislinn Antrim, Managing Editor

Although men are more likely than women to be admitted for a hypertensive crisis, women have similar hospital mortality rates.

The 2-dose Spikevax COVID-19 vaccine was approved by the FDA based on a comprehensive submission package including efficacy and safety data approximately 6 months after the second dose.

The pill molnupiravir and the intravenous drug remdesivir were just as effective against the omicron variant as they were against earlier strains.

The study also found conflicting feelings, as participants seemed overwhelmed by too many recommendations while simultaneously perceiving cancer as an unavoidable death sentence.

Omnipod 5 is the first tubeless automated insulin delivery system that integrates with the Dexcom G6 Continuous Glucose Monitoring System and a compatible smartphone.

Symptoms of depression were reduced as quickly as 1 to 4 hours after a single treatment and lasted up to 2 weeks.

The findings suggest that pregnant women should not delay COVID-19 vaccination until late pregnancy.

Women had lower health-related quality of life at the beginning of the study, although men experienced a more rapid decline over time.

A machine-learning method called XGBoost provided the highest overall accuracy, despite being the least complex model.

The 2 drugs are the first small molecule JAK-1 inhibitors to be approved in the United States as treatment options for patients who are not responding to other therapies.

Nearly two-thirds of respondents had residual feelings of anxiety, depression, or PTSD after using prescription medications.

Early-stage melanomas at risk of spreading secrete the TGFβ2 growth factor, which causes the downregulation of the AMBRA1 and Loricrin proteins.

The FDA also expanded the pediatric emergency use authorization for remdesivir to include the treatment of non-hospitalized pediatric patients at high risk of disease progression.

In a pair of pivotal studies, risankizumab-rzaa (Skyrizi) met the primary endpoint of American College of Rheumatology 20% improvement response at week 24 compared to placebo.

Researchers found similar improvements in dryness, redness, roughness, tightness, irritation, moisturization, smoothness, and overall skin appearance between the 2 products.

New trial results showed statistically significant improvements in overall survival and progression-free survival.

Clinical benefits were seen across subgroups, including patients with squamous and non-squamous lung cancer subtypes, and regardless of PD-L1 levels.

Finding alternative means to promote interleukin 25 could enhance the benefits of fecal transplants in patients with recurrent C. difficile infections.

IMX-110 is a tissue-specific therapeutic designed to accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional therapeutics.

The phase 3 ARASENS trial is the only study prospectively designed to evaluate an androgen receptor inhibitor combined with docetaxel and androgen deprivation therapy in this patient population.

Oral apremilast achieved a clinically meaningful and statistically significant improvement in the primary endpoint of the modified static Physician’s Global Assessment of Genitalia response.

The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.

Approximately 400,000 women undergo breast implant surgeries each year in the United States, and selecting an implant is an important and personal part of the process.

Across the trials, abrocitinib demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity.

The Microbiome Health Index for post-Antibiotic dysbiosis was developed to improve the understanding of and manage the risks associated with antibiotic administration.

The findings could help clinicians tailor the use of early antibiotics in newborns because only infants deemed at risk for infection should receive antibiotics.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

Olive oil consumption increased from 1.6 grams per day in 1990 to approximately 4 grams per day in 2010.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.